JDRF Urges Changes to FDA Policy to Enable Patients to Have Access to Lifesaving Diabetes Technology Sooner
Media Contact: Joana Casas, JDRF, 212.479.7560, firstname.lastname@example.org
Washington, D.C., September 21, 2011 – Yesterday, JDRF submitted comments to the Food and Drug Administration (FDA) on its draft guidance for the testing and approval of a Low Glucose Suspend System (LGS). JDRF commended FDA’s efforts to provide guidance in this area, but strongly warned that the guidance is unreasonable and will further delay the availability of the lifesaving technology to patients who need it. An LGS system is a version of an insulin pump which suspends insulin delivery when a monitor indicates a person with diabetes has or is projected to have dangerously low glucose levels. These systems are the first step toward an artificial pancreas, a device that could transform the lives of individuals with type 1 diabetes.
“This lifesaving technology is already available in over 40 nations around the world, and unfortunately this proposed guidance by the FDA will only further delay access to this system in the United States,” said Jeffrey Brewer, President and CEO of JDRF. “We urge the FDA to resolve three core issues in the guidance to enable people with diabetes to have access to this lifesaving technology as soon as possible.”
JDRF’s three core issues are as follows:
- The proposed clinical study pathway is excessively burdensome, and would further delay patients’ access to the technology. Without changes, this guidance will require multiple clinical trials (inpatient and outpatient) involving a large number of subjects in order to show statistically significant differences in preventing hypoglycemia. This would be an excessive hurdle in order to make available to patients a simple but important feature which shuts off insulin when someone has or is near severe low blood sugar (hypoglycemia). Instead, the LGS systems should be approved based on data showing safety and equivalent glycemic control. Clinical effectiveness data among larger populations could be collected in post-market studies.
- There is a lack of clarity in the use of continuous glucose monitors (CGM) in LGS studies. JDRF is pleased the guidance allows the use of CGM data in evaluating the safety and effectiveness of LGS systems. The use of any other outcomes would be considered impractical by the diabetes research community. FDA must express a commitment to the use of CGM data, rather than indicating it may change its standard later after studies have begun.
- The proposed guidance requires that substitution of substantially equivalent components in the LGS system would be allowed only if additional separate clinical studies of the system for each component variation are conducted. This requirement would severely limit choice for patients and discourage the development of technologies serving a critical public health need. FDA needs to adopt more efficient means to allow sponsors of clinical investigations and holders of approved premarket approval (“PMA”) applications to utilize multiple versions of components or make modifications to their LGS and artificial pancreas systems.
“Millions of people are in desperate need of the LGS system to help manage this disease and prevent life-threatening complications. Nighttime is a particularly dangerous time for a person with diabetes, because an individual’s blood sugar level can drop while they are sleeping, unaware that their levels are too low and unable to do anything about it, leading to seizures, coma, or death,” Brewer stated.
Low glucose suspend systems were a focus of a July 20th hearing in the U.S. House of Representatives Energy and Commerce Committee, which included testimony from a mother of a young woman with type 1 diabetes who has been hospitalized many times from dangerous low blood sugars. A copy of that testimony can be found here.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.
Since its founding in 1970, JDRF has awarded more than $1.7 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. More than 80 percent of JDRF’s expenditures directly support research and research-related education.